¡¡
Pharma Koreana, Korea pharmaceutical news & reports, was established in 1991 and is now Korean leading pharmaceutical business newsletter. For the past years, Pharma Koreana has consistently provided senior executives in the pharmaceutical industry with the inside knowledge they need to compete and win! Readers are subscribers at the pinnacle of their careers as well as the rising stars of tomorrow. They turn to Pharma Koreana for its unique monthly package of Korean pharmaceutical news, analyses, commentaries and data. ¡¡
          
¡¡
There are 21 News items on Display.
Latest News¡¡

HighLight
1. Ilyang¡¯s Supect selected as the best project in terms of the government¡¯s support for preclinical studies

Preclinical and clinical trials for Ilyang Pharm¡¯s Supect (radotinib hydrochloride) cap. had been financially supported by the government. ..
 

April 30th, 2013
2. Fifteen major local pharmaceutical firms reduced sales promotion and entertainment expenses by 10% or more on average in 2012

Analysis of annual reports of fifteen major local pharmaceutical firms showed that these firms recorded an average decrease of 10 percent ..
 

April 30th, 2013
3. Monthly per capita sales of multinational pharmaceutical firms stood at 57 million won on average in 2012

Analysis of annual reports of twenty six multinational pharmaceutical firms showed that these firms recorded annual per capita sales of 685 ..
 

April 30th, 2013
more ...
Business News
4. Average sales growth rate of 68 listed pharmaceutical firms hit rock bottom in 2012 over the past 5 years

The Korea Health Industry Development Institute (KHIDI) reported that sixty eight listed pharmaceutical firms achieved combined sales of 11. ..
 

May 21st, 2013
5. Ildong obtains GMP certification for its antibiotic bulk drugs from PMDA of Japan

Ildong Pharm recently obtained GMP certification for levofloxacin and ofloxacin bulk drugs, produced at its Cheongju plant, from the Pharmac ..
 

May 21st, 2013
6. Chong Kun Dang ranked first in the telmisartan generic drug market in 1Q 2013

Sales of telmisartan products for out-patients were analyzed, based on the UBIST data. In January 2013, telmisartan-containing generic drugs ..
 

May 21st, 2013
7. Locally-developed natural drugs except Stillen showed good performance in 1Q 2013

Sales of locally-developed natural drugs for out-patients were analyzed, based on the UBIST data. As shown in the table, Dong-A¡¯s Motilitone ..
 

May 21st, 2013
8. Hanmi awarded at RFID Journal Awards 2013

Hanmi Pharm won an award at the RFID Journal Awards 2013 recently held in Orlando, the U.S. Since 2009, Hanmi Pharm has promoted a ¡®project ..
 

May 21st, 2013
more ...
Policy and Regulatory
9. Insurance coverage for Viread expected to expand

The Health Insurance Review Agency (HIRA) and the Korean Association for the Study of the Liver (KASI) recently had a meeting to discuss imp ..
 

May 21st, 2013
10. Licensed terms to be revised for valproic acid-containing products

The Ministry of Food and Drug Safety (MFDS) recently ordered post-approval changes in the licensed terms of thirty five valproic acid-contai ..
 

May 21st, 2013
more ...
Bio industry news
11. Quest PharmaTech enrolls the 57th patient in its phase II clinical trial for oregovomab for the treatment of ovarian cancer

Quest Pharma, a local bio-company, previously became the largest stockholder of Quest PharmaTech, a Canada-based biotechnology company. Ques ..
 

May 21st, 2013
12. Unhwa to export 500 billion won worth of plant stem cell-based raw materials

Unhwa, a local plant stem cell research company, recently signed an agreement with Winalite International, a Hongkong-based multinational di ..
 

May 21st, 2013
13. RNL Bio submits its application for the conduction of a phase IIb clinical trial for Jointstem to the US FDA

RNL Bio, a local bio-company, recently filed its Investigational New Drug (IND) application with the US FDA to conduct a phase IIb clinical ..
 

May 21st, 2013
more ...
R & D
14. MFDS approved 149 clinical trial protocols in 1Q 2013

According to a report at a seminar recently held by the Pharmaceutical Manager Society, the Ministry of Food and Drug Safety (MFDS) approved ..
 

May 21st, 2013
15. IND application for JW Pharm¡¯s URC-102 for the treatment of gout approved

JW Pharm recently obtained approval for its Investigational New Drug (IND) application for URC-102 tab. for the treatment of gout from the M ..
 

May 21st, 2013
16. Yuhan and CJ developing new drugs for the treatment of GERD

Yuhan Corp. is currently conducting a phase II clinical trial for YH4808 for the treatment of erosive gastroesophageal reflux disease (GERD) ..
 

May 21st, 2013
more ...
Patent
17. Jeil wins a patent trial over Baraclude

The Korean Intellectual Property Tribunal recently gave a decision that Jeil Pharm¡¯s entecavir product do not infringe BMS¡¯ patent for an en ..
 

May 21st, 2013
18. Chong Kun Dang obtains a US patent for a histone deacetylase inhibitor

Chong Kun Dang recently obtained a US patent titled ¡®novel hydroxamate derivatives, a method for producing the same, and a pharmaceutical co ..
 

May 21st, 2013
19. Hanmi demands a patent trial to nullify a substance patent for Baraclude

Hanmi Pharm recently demanded a patent nullity trial by the Korean Intellectual Property Tribunal, claiming that a substance patent for BMS¡¯ ..
 

May 14th, 2013
more ...
Company profile
20. Summary of Korea pharmaceutical manufacturer

Summary of Korea Pharmaceutical manufacturer (Hanlim Pharm & Kunwha Pharm)Please download the attached file.
 

April 30th, 2013
21. Summary of Korea Pharmaceutical Manufacturer

Summary of Korea Pharmaceutical Manufacturer (Youngjin Pharm)Please download the attached file.
 

April 1st, 2013
more ...
¡¡
Pharma Koreana Ltd. 9F, KAMCO Yangjae Tower, 949-3, Dogok-dong Gangnam-gu, Seoul 135-270, Korea Tel:(82)2-554-9591 Fax:(82)2-563-8289 ¡¡ ¡¡

Email:Pkinfo@Pharmakoreana.com
Subscriptions:Pkinfo@Pharmakoreana.com
¡¡
¡¡